Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
Our transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT...
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
Our transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology.
Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.